In the spirit of the season, this is a view of Merck's (MRK) past, present, and future along the lines of Charles Dickens: A Christmas Carol. The past is the company's downfall from the Vioxx situation and recovery from the accomplishments of achieving multiple new blockbusters. The present is what Merck is currently earning through recent FDA approvals. Merck's future represents the strong growth potential from new FDA approvals from the pipeline along with new add-on acquisitions.
Merck has multiple catalysts that have the potential to drive above average earnings growth over multiple